Embio Diagnostics Ltd
Background
Embio Diagnostics Ltd, established in 2016 and headquartered in Nicosia, Cyprus, is a biotechnology company specializing in the development of innovative, portable biosensor-based devices for rapid diagnostics. The company's mission is to deliver real-time, actionable insights through state-of-the-art sensor technology, empowering businesses, governments, and individuals to make informed decisions. Embio's vision is to revolutionize diagnostics with innovative technologies that foster a healthier and more sustainable future. The company operates globally, serving customers across various sectors, including food safety, environmental monitoring, and healthcare. Embio's flagship products, B.EL.D™ and airbeld™, exemplify its commitment to technological advancement and public health.
Key Strategic Focus
Embio Diagnostics focuses on developing portable, sensor-based diagnostic devices that provide rapid, accurate results across multiple sectors. The company's core objectives include:
- Product Development: Designing and manufacturing innovative diagnostic tools that address critical health and environmental challenges.
- Market Expansion: Entering new global markets to broaden the reach of its diagnostic solutions.
- Technological Integration: Incorporating artificial intelligence and machine learning into diagnostic devices to enhance data analysis and decision-making processes.
Embio specializes in rapid diagnostics for food safety, air quality testing, and environmental research. The company utilizes advanced biosensor technology, IoT integration, and AI-powered analytics to deliver real-time monitoring and predictive diagnostics. Primary markets include Europe, the Middle East, and the United States.
Financials and Funding
Embio Diagnostics has secured significant funding to support its growth and expansion:
- December 2021: Raised €1 million in a seed funding round led by ASBIS Group, a leading distributor of IT and IoT products.
- November 2024: Completed a seed-plus funding round of €2.5 million, led by Kinisis Ventures, with participation from existing and new investors, including a prominent Greek athlete.
The funds are intended to promote Embio's product portfolio internationally, with a focus on markets in the Middle East and the United States. Since 2023, the company has achieved steady export growth, selling its products in over ten countries.
Pipeline Development
Embio Diagnostics is actively developing and expanding its product pipeline:
- B.EL.D™ (Bio Electric Diagnostics): A portable chemical analyzer system that offers rapid diagnostics for food safety, environmental testing, and healthcare applications. The device provides real-time results within minutes, enabling immediate decision-making.
- airbeld™ System: An indoor air quality monitoring solution that leverages AI and sensors to provide real-time data on indoor air pollutants. This system helps users maintain healthier environments by monitoring parameters such as temperature, humidity, CO₂ levels, and particulate matter.
Technological Platform and Innovation
Embio Diagnostics distinguishes itself through several technological innovations:
- Proprietary Technologies: The B.EL.D™ device utilizes biosensor technology for rapid chemical analysis, while the airbeld™ system employs advanced sensors and AI to monitor indoor air quality.
- Scientific Methods: Embio integrates machine learning algorithms into its diagnostic devices to enhance data analysis and predictive capabilities, enabling real-time monitoring and decision-making.
Leadership Team
Embio Diagnostics is led by a team of experienced professionals:
- Constantinos Loizou: CEO and Founder, recognized as the Technology Business Leader of the Year in Cyprus in 2024.
- Savvas Achilleos: Chief Financial Officer
- Lina Kourtella: Chief Operating Officer
- Antonios Inglezakis: Chief Technology Officer
- Dr. Theofylaktos Apostolou: Chief Scientific Officer
- Valia Papadimitriou Loizou: Chief Marketing Officer
- Lazaros Dougiakis: Head of Software Development
- Dr. Agni Hadjilouka: Laboratory Manager
- Maya Obeid: Commercial Director
- George Demetriou: HR Officer
- Ioanna Charalambous: Accounting Officer
- Nikolina Petrovic: Project Manager
- Lazaros Konstantinou: R&D Scientist
- Eleni Varda: Lab Scientist
- Christianthi Kounia: Laboratory Assistant
- Maria Kola: Product Manager
- Marinos Louka: Software and Data Engineer
- David Chatzichristodoulou: Hardware and Electronics Engineer
- Albert Lopez Perez: Embedded Systems Engineer
- Uliya Neronova: Industrial Designer
- Charis Apostolou: UI Designer
- Andreas Komis: Mobile & Frontend Developer
- Marilia Mesiri: Electronics and Hardware Engineer
- Errol Ahmet: Project Manager
- Nikolas Gkevorkian: Key Accounts Specialist
- Ivan Smirnov: Key Accounts Specialist
Market Insights and Dynamics
The global diagnostics market is experiencing significant growth, driven by increasing health awareness, technological advancements, and the need for rapid diagnostic solutions. The market for rapid diagnostics in food safety, air quality, and environmental monitoring is expanding, with a growing emphasis on portable and user-friendly devices.
Competitor Analysis
Embio Diagnostics operates in a competitive landscape with several notable players:
- Fujirebio: A Japanese multinational specializing in in vitro diagnostics, offering a range of diagnostic reagents and instruments.
- EKF Diagnostics: A UK-based company providing point-of-care analyzers and clinical chemistry products.
- bioMérieux: A French multinational offering diagnostic solutions for infectious diseases, cancer screening, and cardiovascular emergencies.
- Epigenomics AG: A German company focused on molecular diagnostics, particularly in oncology.
- Biohit Oyj: A Finnish company developing diagnostic and medical devices, including products for stomach health and smoking cessation.
Strategic Collaborations and Partnerships
Embio Diagnostics has engaged in strategic partnerships to enhance its market presence and technological capabilities:
- ASBIS Group: In December 2021, Embio secured a €1 million investment from ASBIS Group to accelerate growth and enter new global markets.
- Kinisis Ventures: In November 2024, Embio completed a €2.5 million funding round led by Kinisis Ventures, with participation from existing and new investors, including a prominent Greek athlete.
- International WELL Building Institute (IWBI): In January 2025, Embio joined the IWBI as a Cornerstone Member, aligning its airbeld™ system with WELL standards to promote healthier indoor environments.
Operational Insights
Embio Diagnostics differentiates itself through its focus on portable, sensor-based diagnostic devices that provide rapid, accurate results. The company's integration of AI and machine learning into its products enhances data analysis and decision-making processes. Embio's commitment to environmental sustainability and public health positions it as a leader in the diagnostics industry.
